Blueberry anthocyanin intake attenuates the postprandial cardiometabolic effect of an energy-dense food challenge: Results from a double blind, randomized controlled trial in metabolic syndrome participants

BACKGROUND especially in at-risk populations. We therefore examined whether adding blueberries to a high-fat/high-sugar meal affected the postprandial cardiometabolic response over 24 h. METHODS: ) was conducted in participants with metabolic syndrome. After baseline assessments, an energy-dense drink (969 Kcals, 64.5 g fat, 84.5 g carbohydrate, 17.9 g protein) was consumed with either 26 g (freeze-dried) blueberries (equivalent to 1 cup/150 g fresh blueberries) or 26 g isocaloric matched placebo. Repeat blood samples (30, 60, 90, 120, 180, 360 min and 24 h), a 24 h urine collection and vascular measures (at 3, 6, and 24 h) were performed. Insulin and glucose, lipoprotein levels, endothelial function (flow mediated dilatation (FMD)), aortic and systemic arterial stiffness (pulse wave velocity (PWV), Augmentation Index (AIx) respectively), blood pressure (BP), and anthocyanin metabolism (serum and 24 h urine) were assessed. RESULTS: Blueberries favorably affected postprandial (0-24 h) concentrations of glucose (p < 0.001), insulin (p < 0.01), total cholesterol (p = 0.04), HDL-C, large HDL particles (L-HDL-P) (both p < 0.01), extra-large HDL particles (XL-HDL-P; p = 0.04) and Apo-A1 (p = 0.01), but not LDL-C, TG, or Apo-B. After a transient higher peak glucose concentration at 1 h after blueberry intake (8.2 mmol/L, 95%CI: 7.7, 8.8 vs placebo 6.9 mmol/L, 95%CI: 6.4, 7.4; p = 0.001), blueberries significantly attenuated 3 h glucose (4.3 mmol/L, 95%CI: 3.8, 4.8 vs placebo 5.1 mmol/L, 95%CI: 4.6, 5.6; p = 0.03) and insulin concentrations (blueberry: 23.4 pmol/L, 95%CI: 15.4, 31.3 vs placebo 52.9 pmol/L, 95%CI: 41.0, 64.8; p = 0.0001). Blueberries also improved HDL-C (1.12 mmol/L, 95%CI: 1.06, 1.19 vs placebo 1.08 mmol/L, 95%CI: 1.02, 1.14; p = 0.04) at 90 min and XL-HDLP levels (0.38 × 10-6, 95%CI: 0.35, 0.42 vs placebo 0.35 × 10-6, 95%CI: 0.32, 0.39; p = 0.02) at 3 h. Likewise, significant improvements were observed 6 h after blueberries for HDL-C (1.17 mmol/L, 95%CI: 1.11, 1.24 vs placebo 1.10 mmol/L, 95%CI: 1.03, 1.16; p < 0.001), Apo-A1 (1.37 mmol/L, 95%CI: 1.32, 1.41 vs placebo 1.31 mmol/L, 95%CI: 1.27, 1.35; p = 0.003), L-HDLP (0.70 × 10-6, 95%CI: 0.60, 0.81 vs placebo 0.59 × 10-6, 95%CI: 0.50, 0.68; p = 0.003) and XL-HDLP (0.44 × 10-6, 95%CI: 0.40, 0.48 vs placebo 0.40 × 10-6, 95%CI: 0.36, 0.44; p < 0.001). Similarly, total cholesterol levels were significantly lower 24 h after blueberries (4.9 mmol/L, 95%CI: 4.6, 5.1 vs placebo 5.0 mmol/L, 95%CI: 4.8, 5.3; p = 0.04). Conversely, no effects were observed for FMD, PWV, AIx and BP. As anticipated, total anthocyanin-derived phenolic acid metabolite concentrations significantly increased in the 24 h after blueberry intake; especially hippuric acid (6-7-fold serum increase, 10-fold urinary increase). In exploratory analysis, a range of serum/urine metabolites were associated with favorable changes in total cholesterol, HDL-C, XL-HDLP and Apo-A1 (R = 0.43 to 0.50). CONCLUSIONS: For the first time, in an at-risk population, we show that single-exposure to the equivalent of 1 cup blueberries (provided as freeze-dried powder) attenuates the deleterious postprandial effects of consuming an energy-dense high-fat/high-sugar meal over 24 h; reducing insulinaemia and glucose levels, lowering cholesterol, and improving HDL-C, fractions of HDL-P and Apo-A1. Consequently, intake of anthocyanin-rich blueberries may reduce the acute cardiometabolic burden of energy-dense meals. CLINICAL TRIAL REGISTRY: NCT02035592 at www.clinicaltrials.gov.